Targeted inhibition of oncogenic protein BCR::ABL1 with tyrosine kinase inhibitors (TKIs) is a front-line therapy in patients with chronic myeloid leukemia (CML) and Ph + acute lymphoblastic leukemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.